Art. -Nr.: HY-101070

SMCC-DM1

(Synonyms: DM1-SMCC)

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.23%
CAS. Nr.: 1228105-51-8
Formel: C₅₁H₆₆ClN₅O₁₆S
Molecular Weight:1072.61

Speicherung:

-80°C, stored under nitrogen

SMCC-DM1 Chemical Structure

CAS. Nr.: 1228105-51-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC)^[1].

IC₅₀ & Target

Maytansinoids

Alle Drug-Linker Conjugates for ADC Isoform-spezifische Produkte anzeigen :

In Vitro

SMCC-DM1 inhibits HCC1954 and MDA-MB-468 cells proliferation with IC₅₀s of 17.2 and 49.9 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1228105-51-8
Appearance Solid
Molecular Weight 1072.61
Formel C₅₁H₆₆ClN₅O₁₆S
Color White to off-white
SMILES

O=C(O[C@H]([C@@]1(C)[C@H]([C@@H]([C@@]2([H])OC(N[C@]3(O)C2)=O)C)O1)CC(N(C)C4=CC(C/C(C)=C/C=C/[C@H]3OC)=CC(OC)=C4Cl)=O)[C@@H](N(C(CCSC(C5=O)CC(N5CC6CCC(C(ON7C(CCC7=O)=O)=O)CC6)=O)=O)C)C
Synonyms

DM1-SMCC
Versand

Shipping with dry ice.
Speicherung

-80°C, stored under nitrogen

Publications (12)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIFWB

Sort by:

Journal Impact Factor

Cancer Lett

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. [Abstract]

2023 Feb 1:554:216024. PMID: 36455759

SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]

SMCC-DM1 (10 mM). Dose-response analysis of the effect of cetuximab-DM1 (1-100000 nM; 120 h) on the proliferation of parental HCC1954 and HCC-TDM1R cells. IC₅₀ values were represented in the graph and detailed in the table.

SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]

SMCC-DM1 (10 mM). In vivo effect of cetuximab-DM1 (i.p.; 15 mg/kg) on tumor growth in BALB/c nu/nu mice injected with HCC1954, HCC-TDM1R#19, or HCCTDM1R#20 cells.

SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]

SMCC-DM1 (10 mM). Colocalization (yellow) between cetuximab-DM1 (cet-DM1) (30 min-24 h; 10 nM) and LAMP1 occurred at the indicated incubation times in HCC1954 and HCC-TDM1R cells. Cetuximab-DM1 staining red, LAMP1: green, DAPI: blue.

SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]

SMCC-DM1 (10 mM). Western blot analyses showed the effect of cetuximab-DM1 (10 nM; 1-3 d) on the EGFR levels in HCC1954 and HCC-TDM1R cells.
Mol Ther

Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy. [Abstract]

2022 Jul 6;30(7):2522-2536. PMID: 35440418

SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2022 Jul 6;30(7):2522-2536. [Abstract]

ScFab Pigbak#2 and SMCC-DM1 were mixed in a molar ratio of 1:10 in PBS (pH 7.5) at 4 ℃ overnight. B16F10 cells were incubated with Pigbak#2-DM1 (0.05-50 nM) at various concentrations.
Int J Biol Macromol

Anovel anti-B7-H3 nanobody and its DM1 conjugate with marked anti-tumor activity against esophageal squamous cell carcinoma. [Abstract]

2025 Aug 20;322(Pt 4):147025. PMID: 40846015
Int J Mol Sci

A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. [Abstract]

2022 Oct 15;23(20):12358. PMID: 36293219
mBio

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. [Abstract]

2022 Feb 22;13(1):e0338421. PMID: 35038908
J Pharm Sci

Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads. [Abstract]

2024 Aug;113(8):2443-2453. PMID: 38679234
J Pharm Sci

Agitation-Induced Aggregation of Lysine- and Interchain Cysteine-Linked Antibody-Drug Conjugates. [Abstract]

2024 May;113(5):1265-1274. PMID: 38070776
AAPS J

Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy. [Abstract]

2025 May 9;27(4):91. PMID: 40341444
Patent

US20260000782A1.
Patent

US20250163175A1.
Patent

US20250041438A1.
Monoclon Antib Immunodiagn Immunother

Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model. [Abstract]

2020 Apr;39(2):37-44. PMID: 32182186

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 16.67 mg/mL (15.54 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9323 mL

4.6615 mL

9.3231 mL

5 mM

0.1865 mL

0.9323 mL

1.8646 mL

10 mM

0.0932 mL

0.4662 mL

0.9323 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (1.56 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (1.56 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (1.56 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018 May 1;28(8):1363-1370. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9323 mL	4.6615 mL	9.3231 mL	23.3076 mL
	5 mM	0.1865 mL	0.9323 mL	1.8646 mL	4.6615 mL
	10 mM	0.0932 mL	0.4662 mL	0.9323 mL	2.3308 mL
	15 mM	0.0622 mL	0.3108 mL	0.6215 mL	1.5538 mL

Keywords

SMCC-DM1

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SMCC-DM1

Publications Citing Use of MedChemExpress (MCE) SMCC-DM1

Alle Drug-Linker Conjugates for ADC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SMCC-DM1 Related Classifications

HY-101070 Related Classifications